Immunotoxins are cytolytic fusion proteins developed for cancer therapy, composed of an
antibody fragment that binds to a cancer cell and a protein toxin fragment that kills the cell …

The repurposing of the CRISPR/Cas microbial adaptive immune system for gene editing has
resulted in an exponential rise in new technologies and promising approaches for treating …

Cancer is one of the leading causes of mortality and morbidity worldwide. According to 2022
statistics from the World Health Organization (WHO), close to 10 million deaths have been …

Abstract The 2019 13th Workshop on Recent Issues in Bioanalysis (WRIB) took place in
New Orleans, LA, USA on April 1–5, 2019 with an attendance of over 1000 representatives …

Evolving immunogenicity assay performance expectations and a lack of harmonized
neutralizing antibody validation testing and reporting tools have resulted in significant time …

Background In a multicenter phase 1 study of children with relapsed/refractory acute
lymphoblastic leukemia (ALL), moxetumomab pasudotox, an anti‐CD22 immunotoxin …

Despite recent advances in the development of tools to predict immunogenicity risk of
biotherapeutic molecules, the ability of a protein to elicit the formation of anti-drug antibodies …

Anti-drug antibodies (ADA) pose a potential risk to patient safety and efficacy and are
routinely monitored during clinical trials. Pre-existing drug-reactive antibodies are present in …

Upon reformatting of an antibody to single-chain variable fragment format, a region in the
former variable/constant domain interface of the heavy chain becomes accessible for …

Background: Therapy for acute lymphoblastic leukemia (ALL) are currently initially efficient,
but even if a high percentage of patients have an initial complete remission (CR), most of …